Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07595094

Phenotypic Age Acceleration (PhenoAgeAccel) for Joint Prediction of Disease Risk, Mortality Risk, Life Expectancy, and Disease-Free Healthspan in Major Chronic Diseases

The goal of this observational study is to learn about the ability of Phenotypic Age Acceleration (PhenoAgeAccel) to predict four key health outcomes in Chinese people with or at risk of major chronic diseases: the risk of developing new chronic diseases, the risk of dying, life expectancy, and disease-free healthspan.

The main questions this study aims to answer are:

* Does higher PhenoAgeAccel increase the risk of developing major chronic diseases (including diabetes, dementia, cancer, and chronic respiratory diseases) in Chinese adults? * Does higher PhenoAgeAccel increase the risk of death from all causes in Chinese adults? * How do life expectancy and disease-free healthspan differ between people with high versus low PhenoAgeAccel?

Who can take part in this study? Adults aged 35 or above years old who receive routine care at participating hospitals in China, have complete routine blood test data available, and have provided consent to use their health information for research purposes.

What will participants go through? Participants will receive their usual medical care as they normally would. No new treatments, tests, or procedures will be performed specifically for this study. We will collect data from their medical records, including blood test results used to calculate PhenoAgeAccel, diagnoses of new diseases, and dates of death.

What are the potential benefits? Participants will not receive direct personal benefits from taking part in this study. However, the information learned may help us better understand biological aging and improve future risk assessment and health management for people with chronic diseases.

Is this study safe? Yes. This is an observational study that does not involve any new drugs, devices, or invasive procedures. All data used in the study will be de-identified and kept strictly confidential to protect participants' privacy.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Phenotypic Age Acceleration Biological Aging Marker Chinese Population Disease Risk Prediction Disease-Free Healthspan Life Expectancy Mortality Risk Prediction Observational Cohort Study

Age range

35 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 35-73 years old. Complete routine blood test data available at baseline to calculate Phenotypic -Age (including albumin, alkaline phosphatase, creatinine, glucose, C-reactive protein, lymphocyte percentage, mean corpuscular volume, red cell distribution width, and white blood cell count).

Complete demographic and clinical data (e.g., sex, BMI, comorbidities) available at baseline.

  • Consent to use routine medical data for research follow-up analysis.

Exclusion criteria

  • Presence of end-stage diseases (e.g., end-stage liver/renal failure) other than the major chronic diseases of interest at baseline.
  • Key baseline data missing, making Phenotypic Age calculation impossible. Incomplete follow-up information or inability to confirm outcomes (e.g., death, disease onset) via database linkage.
  • Refusal to participate in the study or withdrawal of informed consent.

Treatment and study plan

No intervention (observational study)

Other

This is an observational study with no study-specific intervention. All participants receive their routine standard medical care as usual. No new drugs, devices, procedures, or behavioral modifications are assigned as part of this research.

Primary outcomes

  1. Incidence of Major Chronic Diseases

    Time frame: Baseline through study completion, average 10 years

    Composite incidence of new-onset major chronic diseases, including type 2 diabetes, dementia, cancer, and chronic respiratory diseases, defined by ICD-10 codes from electronic medical records.

  2. All-Cause Mortality

    Time frame: Baseline through study completion, average 10 years

    All-cause mortality, defined as death from any cause, identified through linkage with death registration databases.

Secondary outcomes

  1. Life Expectancy

    Time frame: Baseline through study completion, average 10 years

    Estimated remaining life expectancy stratified by biological aging status (PhenoAgeAccel) using parametric survival models.

  2. Disease-Free Healthspan

    Time frame: Baseline through study completion, average 10 years

    Estimated years of life free from major chronic diseases, calculated as the difference between life expectancy and time spent with chronic diseases

Study contacts

Contact information is provided by the study sponsor or research team.

Xi-jian Dai, Doctor

CONTACT

[email protected]

13755756959

Sponsors and collaborators

Lead sponsor

Second Affiliated Hospital of Nanchang University

Other

Registry information

Important dates

Study start
2006
Primary completion
2030
Study completion
2030
First posted
May 19, 2026
Registry last updated
May 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.